Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.
用于前列腺癌鉴别诊断的 MRI 造影剂的商业化。
基本信息
- 批准号:9534548
- 负责人:
- 金额:$ 99.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-21 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffinityAggressive behaviorAnimal ModelAppearanceBindingBiodistributionBiopsyBlood ScreeningCancer EtiologyCarcinomaCellsCessation of lifeClinicalClinical DataClinical ManagementClinical TrialsContrast MediaDataDecision MakingDetectionDevelopmentDiagnosisDiagnostic ImagingDiagnostic ProcedureDifferential DiagnosisDiseaseDisease ProgressionDoseDrug KineticsEarly DiagnosisEffectivenessErectile dysfunctionExtracellular MatrixFDA approvedFormulationFreeze DryingGoalsHourHumanImageryImaging TechniquesImaging technologyIndolentIntestinesLeadLesionLethal Dose 50LocationMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of prostateMetabolic Clearance RateMethodsMissionModelingMolecularMolecular TargetMonitorMusNeoplasm MetastasisNo-Observed-Adverse-Effect LevelNoiseNormal tissue morphologyOncoproteinsOperative Surgical ProceduresOsmolalitiesPC3 cell linePatientsPharmacologyPhasePhysiciansPlasmaProductionProhanceProstateProstate Cancer therapyProstate-Specific AntigenProstatic NeoplasmsProteinsRadiationRattusRenal clearance functionResidual stateRiskRisk stratificationRodentSafetyScreening for Prostate CancerSensitivity and SpecificitySmall Business Innovation Research GrantStructureTemperatureTestingTimeTissuesToxic effectUltrasonographyUrinary IncontinenceUrologistWaterXenograft procedureactive methodangiogenesisaqueousbasecancer cellcancer imagingcancer riskclinical diagnosticsclinical imagingclinical translationcommercializationcontrast enhancedcost effectiveepithelial to mesenchymal transitionhigh resolution imaginghigh riskimage guided therapyimaging agentimaging approachimprovedinnovationmenmolecular imagingmortalitynoveloverexpressionpreclinical studypreventprocedure costprostate biopsyprostate cancer riskreconstitutionsafety studyscale upscreeningstemnesstheranosticstherapy outcometooltumor
项目摘要
Abstract
Prostate cancer is a highly heterogeneous disease and the second most cause of cancer death of
men in the US. Current methods to assess prostate cancer risk combine prostate specific antigen (PSA)
screening and random prostate biopsy. Unfortunately, this strategy fails to reveal the lesion’s location and
does not accurately differentiate between aggressive and non-aggressive prostate cancers. As a result,
most patients will receive unnecessary active treatment for low-risk prostate cancer in order to avoid
under treatment. Active treatment involves surgery or radiation, often causing long-term side effects such
as urinary incontinence, erectile dysfunction, or bowel urgency. Thus, development of non-invasive and
accurate diagnostic imaging technology to localize and differentiate high-risk prostate cancer offer a new
tool to assist physicians in risk-stratification and decision making and to spare millions patients with low-
risk cancer from unnecessary aggressive treatment.
The mission of Molecular Theranostics (fka Prostate Theranostics) is to commercialize a novel
molecular imaging approach that targets an oncoprotein associated with epithelial-to-mesenchymal
transition (EMT), cancer cell stemness, angiogenesis, proliferation, and metastasis. The oncoprotein has
a high expression in the tumor extracellular matrix of high-risk prostate cancer, low in low-grade tumor,
none in normal tissues. The goal of this project is to commercialize a safe and effective targeted contrast
agent for accurate early detection, localization, and differential diagnosis of high-risk prostate cancer with
MRI. In phase I, we have optimized and identified a lead targeted MRI contrast agent for clinical
translation. All of the milestones in Phase I of the project have been achieved. The agent possesses the
superior ability of robust specific contrast enhancement in high-risk prostate cancer, not in slow growing
low-risk tumors in animal models, and has the potential to visualize and differentiate high-risk prostate
cancers with MRI.
The objectives of this SBIR Phase II are to develop a lead formulation of the contrast agent, to
perform FDA required eIND enabling studies, and to commercialize the agent for clinical imaging prostate
cancer. The specific aims are 1) to scale up the synthesis of the targeted contrast agent and develop a
lead product formulation for pre-clinical study and clinical trials; 2) to validate the effectiveness of the
formulation for prostate cancer imaging on a clinical MRI scanner and to determine its minimally effective
dose; 3) to perform eIND-enabling pharmacokinetics and safety studies in rodents. Non-invasive accurate
detection of prostate cancer is an unmet clinical need for prostate cancer management. Clinical trials will
be initiated as soon as the eIND is approved by the FDA. Successful development of our imaging
technology has the potential to accurately detect, localize, and diagnose prostate cancer, replace
invasive prostate biopsy, and improve decision-making in clinical management of prostate cancer. It also
has the potential for non-invasive active surveillance of prostate cancer and timely monitoring of disease
progression, as well as image-guided therapy.
摘要
前列腺癌是一种高度异质性的疾病,并且是癌症死亡的第二大原因。
男人在美国。目前评估前列腺癌风险的方法结合了联合收割机前列腺特异性抗原(PSA)
筛查和随机前列腺活检。不幸的是,这种策略无法揭示病变的位置,
不能准确区分侵袭性和非侵袭性前列腺癌。因此,在本发明中,
大多数患者将接受不必要的低风险前列腺癌积极治疗,以避免
正在接受治疗积极的治疗包括手术或放射治疗,通常会引起长期的副作用,
如尿失禁勃起功能障碍或肠紧迫。因此,非侵入性和
准确的诊断成像技术,以定位和区分高危前列腺癌提供了一个新的
帮助医生进行风险分层和决策的工具,
不必要的积极治疗会导致癌症。
分子治疗学的使命(fka前列腺治疗学)是将一种新的
一种靶向与上皮间质相关的癌蛋白的分子成像方法
转化(EMT)、癌细胞干细胞性、血管生成、增殖和转移。癌蛋白具有
在高危前列腺癌的肿瘤细胞外基质中高表达,在低级别肿瘤中低表达,
正常组织中无。该项目的目标是将安全有效的靶向造影剂商业化
用于准确早期检测、定位和鉴别诊断高危前列腺癌的试剂,
核磁共振在第一阶段,我们已经优化并确定了一种用于临床的主要靶向MRI造影剂,
翻译.该项目第一阶段的所有里程碑都已实现。代理拥有
在高危前列腺癌中,而不是在缓慢生长的前列腺癌中,稳健的特异性对比增强的上级能力
在动物模型中的低风险肿瘤,并有可能可视化和区分高风险前列腺
癌症MRI
SBIR第II阶段的目标是开发造影剂的主要配方,
进行FDA要求的eIND使能研究,并将用于前列腺临床成像的药物商业化
癌具体目标是:1)按比例扩大靶向造影剂的合成,并开发一种靶向造影剂。
临床前研究和临床试验的主导产品配方; 2)验证
用于在临床MRI扫描仪上进行前列腺癌成像的制剂,并确定其最低有效性
剂量; 3)在啮齿动物中进行eIND使能药代动力学和安全性研究。无创精确
前列腺癌的检测是前列腺癌管理的未满足的临床需求。临床试验将
一旦eIND获得FDA批准,就立即启动。成功开发我们的成像技术
技术有可能准确地检测,定位和诊断前列腺癌,取代
侵入性前列腺活组织检查和改善前列腺癌临床管理决策。它还
具有非侵入性主动监测前列腺癌和及时监测疾病的潜力
进展以及图像引导治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yajuan Li其他文献
Yajuan Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yajuan Li', 18)}}的其他基金
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer
用于前列腺癌鉴别诊断的 MRI 造影剂的商业化
- 批准号:
10481722 - 财政年份:2022
- 资助金额:
$ 99.97万 - 项目类别:
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.
用于前列腺癌鉴别诊断的 MRI 造影剂的商业化。
- 批准号:
10013075 - 财政年份:2015
- 资助金额:
$ 99.97万 - 项目类别:
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.
用于前列腺癌鉴别诊断的 MRI 造影剂的商业化。
- 批准号:
9984635 - 财政年份:2015
- 资助金额:
$ 99.97万 - 项目类别:
Commercialization of targeted MRI contrast agents for prostate cancer imaging.
用于前列腺癌成像的靶向 MRI 造影剂的商业化。
- 批准号:
8979024 - 财政年份:2015
- 资助金额:
$ 99.97万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 99.97万 - 项目类别:
Continuing Grant